Glucocorticoid receptor expression and antiproliferative effect of dexamethasone on human melanoma cells

Judit Dobos1, István Kenessey, József Tímár

  • 1Center of Surgical and Molecular Tumor Pathology, National Institute of Oncology, Budapest, Hungary. dobosj76@gmail.com

Insights

Dexamethasone, a glucocorticoid, induces apoptosis and inhibits growth in human melanoma cells. It also enhances the efficacy of chemotherapy drug DTIC in these cancer cells.

Area of Science:

  • Oncology
  • Endocrinology
  • Molecular Biology

Background:

  • Glucocorticoids like dexamethasone are utilized in cancer treatment.
  • These steroids exhibit varied effects on cell death pathways, depending on cell type.
  • The impact of dexamethasone on melanoma cells remains incompletely understood.

Purpose of the Study:

  • To investigate the sensitivity of human melanoma cells to dexamethasone treatment.
  • To determine the presence and role of the glucocorticoid receptor (GCR) in melanoma.
  • To evaluate dexamethasone's potential as a sensitizer for chemotherapy in melanoma.

Main Methods:

  • Analysis of glucocorticoid receptor (GCR) mRNA and protein expression in melanoma cell lines and tumors.
  • In vitro assessment of dexamethasone's effect on WM983A human melanoma cell growth.
  • Evaluation of dexamethasone's impact on apoptosis induction.
  • Combination studies with dexamethasone and the chemotherapeutic drug DTIC.

Main Results:

  • Glucocorticoid receptor (GCR) was detected at both mRNA and protein levels in human melanoma cell lines and tumors.
  • High-dose dexamethasone significantly inhibited the in vitro growth of WM983A melanoma cells.
  • The growth inhibition was attributed to the induction of apoptosis.
  • Dexamethasone potentiated the anti-cancer effect of DTIC in this melanoma cell line.

Conclusions:

  • Human melanoma cells express the glucocorticoid receptor (GCR).
  • Dexamethasone exhibits anti-proliferative and pro-apoptotic effects on human melanoma cells.
  • Dexamethasone may serve as a valuable adjuvant therapy to enhance chemotherapy efficacy in melanoma treatment.